AAV VP1 Initiation Codon Control for Insect-Cell Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing AAV production systems, particularly in mammalian cells, face challenges such as low yield and contamination risks, while insect cell-based systems suffer from reduced infectivity and stability issues, especially for AAV5 vectors.
Innovation Solution
A nucleic acid molecule with a modified open reading frame using suboptimal translation initiation codons (CTG, ACG, TTG, GTG) and additional codons for amino acids, linked to expression control sequences, enhances AAV capsid protein expression and stability in insect cells, specifically for AAV serotypes 5, 8, and 9.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV production is performed in mammalian cells, then high infectivity is achieved, but production yield is limited and contamination risk increases
Solution Approach 1:
The patent modifies the translation initiation codon from the optimal ATG to suboptimal codons (CTG, ACG, TTG, or GTG) to reduce VP1 protein expression levels. This parameter change in the coding sequence allows adjustment of protein stoichiometry to match the limited capacity of mammalian cell production systems while maintaining correct capsid assembly and infectivity.
Solution Approach 2:
The invention applies a localized modification only to the VP1 coding region's initiation codon, leaving the rest of the capsid protein sequences unchanged. This localized change specifically addresses the overexpression problem of VP1 without affecting the overall capsid structure or function, allowing production in mammalian cells to achieve both reasonable yield and maintained infectivity.
2Productivity
If AAV production is performed in insect cells, then production yield increases, but infectivity is reduced due to incorrect capsid protein stoichiometry
Solution Approach 1:
The patent changes the translation initiation codon to suboptimal codons (CTG, ACG, TTG, or GTG) to reduce VP1 expression levels in insect cells. This parameter change corrects the stoichiometry imbalance that normally occurs in insect cell production, enabling high-yield production while maintaining proper capsid composition and infectivity.
3Productivity
If VP1 expression is increased to improve capsid assembly, then production yield increases, but protein stoichiometry becomes unbalanced
Solution Approach 1:
The invention modifies the translation initiation codon to a suboptimal codon, which directly controls the expression level of VP1 protein. This parameter change reduces VP1 expression to appropriate levels, maintaining correct protein stoichiometry (VP1:VP2:VP3 ratio) while still enabling sufficient production yield for practical applications.
Data Source
AI summary
The present invention relates to the production of adeno-associated viral vectors in insect cells. The insect cells therefore comprise a first nucleotide sequence encoding the adeno-associated virus (AAV) capsid proteins, whereby the initiation codon for translation of the AAV VP1 capsid protein is a non-ATG, suboptimal initiation codon and wherein the coding sequence for one or more amino acid residues have been inserted between the suboptimal translation initiation codon and the codon encoding the amino acid residue that corresponds to the amino acid residue at position 2 of the wild type capsid amino acid sequence of which the first amino acid residue is alanine, glycine, valine, aspartic acid or glutamic acid. The insect cell further comprises a second nucleotide sequence comprising at least one AAV inverted terminal repeat (ITR) nucleotide sequence; a third nucleotide sequence comprising a Rep52 or a Rep40 coding sequence operably linked to expression control sequences for expression in an insect cell; and, a fourth nucleotide sequence comprising a Rep78 or a Rep68 coding sequence operably linked to expression control sequences for expression in an insect cell. The invention further relates to adeno-associated viral vectors with an altered ratio of the viral capsid proteins.